CPRX Stock Analysis: Buy, Sell, or Hold?
CPRX - Catalyst Pharmaceutical Inc.
$31.38
-0.02 (-0.06%)
▼
5d:
+0.03%
30d:
+0.54%
90d:
+40.53%
HOLD
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.5/10
Get Alerted When CPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CPRX is fairly valued with market pricing in 3.1% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: CPRX is fairly valued with market pricing in 3.1% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$52.44
Based on 13.1% avg growth
INTRINSIC VALUE TODAY
$32.56
3.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CPRX is currently trading at $31.38, which is considered extended relative to its 30-day fair value range of $31.20 to $31.35. The stock's valuation (Forward PE: 9.9) is in line with its historical norms (9.0). At these levels, the market is pricing in 3.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CPRX is in a strong uptrend. The price is currently testing key support at $31.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CPRX is in a strong uptrend. The price is currently testing key support at $31.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$31.20 -
$31.35
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.1%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($31.67)
- NEUTRAL: Market pricing in 3.1% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$31.20 -
$31.35
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$31.27
Resistance Level
$31.40
Current Trend
Strong Uptrend
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.86
Wall Street Target
$31.67
(+0.9%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
11.1%
Profit Margin
37.1%
Valuation Premium vs History
+3.1% premium
PE vs Historical
9.9 vs 9.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.1%
(market-implied from PE analysis)
1-Year Target
$32.35
(+3%)
2-Year Target
$33.36
(+6%)
3-Year Target
$34.39
(+10%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$31.38
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 22.1%)
$69.74
(+122%)
Base:
(SPY PE: 9.9, Growth: 22.1%)
$31.59
(+1%)
Bear:
(PE: 8.4, Growth: 22.1%)
$26.85
(-14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 18.15 | Current EPS (TTM): $1.73
Bull Case
$63.51
(+102%)
Analyst growth 83.9%, PE expands to 20.0
Base Case
$57.74
(+84%)
Market implied 83.9%, PE stable at 18.2
Bear Case
$21.35
(-32%)
Severe decline -20.0%, PE contracts to 15.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 19, 2026 1:35 AM ET
Data refreshes hourly during market hours. Next update: 2:35 AM
Data refreshes hourly during market hours. Next update: 2:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 51 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 53 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$39 | 63 BUY |
